These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 6338971)

  • 21. Pyridoxal phosphate as an antisickling agent in vitro.
    Kark JA; Tarassoff PG; Bongiovanni R
    J Clin Invest; 1983 May; 71(5):1224-9. PubMed ID: 6853710
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Triazole Disulfide Compound Increases the Affinity of Hemoglobin for Oxygen and Reduces the Sickling of Human Sickle Cells.
    Nakagawa A; Ferrari M; Schleifer G; Cooper MK; Liu C; Yu B; Berra L; Klings ES; Safo RS; Chen Q; Musayev FN; Safo MK; Abdulmalik O; Bloch DB; Zapol WM
    Mol Pharm; 2018 May; 15(5):1954-1963. PubMed ID: 29634905
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Current status of methyl acetimidate as an extracorporeal antisickling agent.
    Chao TL; Berenfeld MR; Gabuzda TG
    Am J Pediatr Hematol Oncol; 1984; 6(1):55-8. PubMed ID: 6711765
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeted modification of furan-2-carboxaldehydes into Michael acceptor analogs yielded long-acting hemoglobin modulators with dual antisickling activities.
    Omar AM; Abdulmalik O; El-Say KM; Ghatge MS; Cyril-Olutayo M; Paredes S; Al-Awadh M; El-Araby ME; Safo MK
    Chem Biol Drug Des; 2024 Jan; 103(1):e14371. PubMed ID: 37798397
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Quantitative prediction of erythrocyte sickling for the development of advanced sickle cell therapies.
    Lu L; Li Z; Li H; Li X; Vekilov PG; Karniadakis GE
    Sci Adv; 2019 Aug; 5(8):eaax3905. PubMed ID: 31457104
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of urea and cyanate on sickling in vitro.
    Segel GB; Feig SA; Mentzer WC; McCaffrey RP; Wells R; Bunn HF; Shohet SB; Nathan DG
    N Engl J Med; 1972 Jul; 287(2):59-64. PubMed ID: 5031386
    [No Abstract]   [Full Text] [Related]  

  • 27. The effect of phenylalanine derivatives on the solubility of deoxyhemoglobin S. A model class of gelation inhibitors.
    Noguchi CT; Ackerman S; DiMaio J; Schiller PW; Schechter AN
    Mol Pharmacol; 1983 Jan; 23(1):100-3. PubMed ID: 6865893
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Noncovalent modification of deoxyhemoglobin S solubility and erythrocyte sickling.
    Waterman MR; Yamaoka K; Dahm L; Taylor J; Cottam GL
    Proc Natl Acad Sci U S A; 1974 Jun; 71(6):2222-5. PubMed ID: 4526343
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Identification of 2-imidazolines as anti-sickling agents.
    Chang H; Ewert SM; Nagel RL
    Mol Pharmacol; 1983 May; 23(3):731-4. PubMed ID: 6865916
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mechanism of inhibition of sickling by dimethyl adipimidate. Effects of intertetramer cross-linking.
    Pennathur-Das R; Heath R; Mentzer W; Lubin B
    Biochim Biophys Acta; 1984 Dec; 791(2):259-64. PubMed ID: 6509069
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prolongation of sickle cell survival by dimethyl adipimidate is compromised by immune sensitization.
    Guis MS; Lande WM; Mohandas N; Pennathur-Das R; Preisler H; Lubin BH; Mentzer WC
    Blood; 1984 Jul; 64(1):161-5. PubMed ID: 6733268
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Potassium cyanate as an inhibitor of the sickling of erythrocytes in vitro.
    Cerami A; Manning JM
    Proc Natl Acad Sci U S A; 1971 Jun; 68(6):1180-3. PubMed ID: 5288366
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Quantitation of red cell deformability during progressive deoxygenation and oxygenation in sickling disorders (the use of an automated Ektacytometer).
    Bessis M; Feo C; Jones E
    Blood Cells; 1982; 8(1):17-28. PubMed ID: 7115975
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Deoxyhemoglobin S gelation and insolubility at high ionic strength are distinct phenomena.
    Roth EF; Bookchin RM; Nagel RL
    J Lab Clin Med; 1979 May; 93(5):867-71. PubMed ID: 429878
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cyanate as an inhibitor of red-cell sickling.
    Cerami A
    N Engl J Med; 1972 Oct; 287(16):807-12. PubMed ID: 4560520
    [No Abstract]   [Full Text] [Related]  

  • 36. Adaptation of a microbead assay for the easy evaluation of traditional anti-sickling medicines: application to DREPANOSTAT and FACA.
    Villaret J; Marti G; Dubois F; Reybier K; Gaudre N; Haddad M; Valentin A
    Pharm Biol; 2018 Dec; 56(1):385-392. PubMed ID: 30261794
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of cetiedil, an in vitro antisickling agent, on erythrocyte membrane cation permeability.
    Berkowitz LR; Orringer EP
    J Clin Invest; 1981 Nov; 68(5):1215-20. PubMed ID: 7298848
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bencyclane as an anti-sickling agent.
    Koçak R; Başlamişli F; Güvenç B; Tamer L; Aikimbaev KS; Isbir T
    Br J Haematol; 1996 Feb; 92(2):329-31. PubMed ID: 8602994
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sickle cell anemia and antisickling agents then and now.
    Mehanna AS
    Curr Med Chem; 2001 Feb; 8(2):79-88. PubMed ID: 11172667
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeting HbS Polymerization.
    Ferrone FA
    Semin Hematol; 2018 Apr; 55(2):53-59. PubMed ID: 30616807
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.